US2014056931A1PendingUtilityA1

Genetic adjuvants for immunotherapy

66
Individually held — no corporate assignee on recordPriority: Sep 5, 2002Filed: Nov 6, 2013Published: Feb 27, 2014
Est. expirySep 5, 2022(expired)· nominal 20-yr term from priority
Inventors:Shyam S. MohapatraMukesh Kumar
A61K 39/39A61K 2039/55538A61K 38/217A61K 38/208A61K 2039/53A61K 39/36A61K 2039/55522A61P 37/04A61K 39/35
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions of the invention contain nucleic acid molecules encoding IL-12 and/or IFN-γ and an operably-linked promoter sequence. In another aspect, the present invention concerns expression vectors containing a nucleotide sequence encoding IL-12 and IFN-γ, and an operably-linked promoter sequence. In another aspect, the present invention concerns cells genetically modified with a nucleotide sequence encoding IL-12 and IFN-γ.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for modulating an immune response in order to treat an immune-related or inflammatory-related condition, comprising administering a nucleic acid sequence encoding IL-12, IFN-γ, or both IL-12 and IFN-γ, or biologically active fragments of any of the foregoing; and an operably-linked promoter sequence; to a patient in need thereof. 
     
     
         2 . The method of  claim 1 , wherein the immune-related or inflammatory condition is selected from among allergy, allergic rhinitis, atopic dermatitis, asthma, allergic sinusitis, pulmonary fibrosis, and cancer. 
     
     
         3 . The method of  claim 1 , wherein the nucleic acid sequence encodes human IL-12, human IFN-γ, or both human IL-12 and human IFN-γ. 
     
     
         4 . The method of  claim 1 , wherein the IL-12 comprises the p35 subunit, the p40 subunit, or both the p35 subunit and the p40 subunit. 
     
     
         5 . The method of  claim 4 , wherein the p35 subunit comprises the amino acid sequence of SEQ ID NO:8, or a biologically active fragment or homolog thereof, and wherein the p40 subunit comprises the amino acid sequence of SEQ ID NO:10, or a biologically active fragment or homolog thereof. 
     
     
         6 . The method of  claim 1 , wherein the nucleic acid sequence encodes both IL-12 and IFN-γ. 
     
     
         7 . The method of  claim 1 , wherein the IFN-γ comprises the amino acid sequence of SEQ ID NO:12, or a biologically active fragment or homolog thereof. 
     
     
         8 . The method of  claim 1 , wherein the nucleic acid sequence encoding IL-12, or both IL-12 and IFN-γ, comprises SEQ ID NO:7 or SEQ ID NO:9, or a biologically active fragment or homolog of any of the foregoing. 
     
     
         9 . The method of  claim 1 , wherein the nucleic acid sequence encoding IFN-γ, or both IL-12 and IFN-γ, comprises SEQ ID NO:11, or a biologically active fragment or homolog thereof. 
     
     
         10 . The method of  claim 1 , wherein the nucleic acid sequence is administered with a pharmaceutically acceptable carrier. 
     
     
         11 . The method of  claim 1 , wherein the nucleic acid sequence is contained within an expression vector. 
     
     
         12 . The method of  claim 11 , wherein the expression vector is a DNA plasmid. 
     
     
         13 . The method of  claim 11 , wherein the expression vector is a viral vector. 
     
     
         14 . The method of  claim 1 , wherein the nucleic acid sequence is contained within a genetically modified cell that expresses the nucleic acid sequence within the patient. 
     
     
         15 . The method of  claim 1 , further comprising administering an antigen to the patient. 
     
     
         16 . The method of  claim 15 , wherein the antigen is selected from the group consisting of a protein, peptide, glycoprotein, carbohydrate, lipid, glycolipid, hapten conjugate, recombinant nucleotides, killed or attenuated organism, toxin, toxoid, and organic molecule. 
     
     
         17 . The method of  claim 15 , wherein the antigen is administered to the patient as a non-antigenic nucleotide sequence encoding an antigenic polypeptide. 
     
     
         18 . The method of  claim 15 , wherein the antigen is an antigenic nucleotide sequence. 
     
     
         19 . The method of  claim 15 , wherein the antigen is administered to the patient with the nucleic acid sequence and a pharmaceutically acceptable carrier. 
     
     
         20 . The method of  claim 1 , wherein the patient is human.

Join the waitlist — get patent alerts

Track US2014056931A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.